Withdrawal of fenofibrate treatment partially abrogates preventive neuroprotection in stroke via loss of vascular protection

Vascular Pharmacology

Volumn 51, Issue 5-6, 2009, Pages 323-330

  Ouk, Thavarak ^a   Laprais, Maud ^a   Bastide, Michèle ^a   Mostafa, Kouach ^b   Gautier, Sophie ^a   Bordet, Régis ^a  

^a Institut de Médecine Prédictive et de Recherche Thérapeutique   (France)

^b UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

Author keywords

Cerebral ischaemia; Endothelium; Inflammation; Oxidative stress; PPAR

Indexed keywords

FENOFIBRATE; FENOFIBRIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL ACTIVATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; INFLAMMATION; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STROKE;

ACETYLCHOLINE; ANIMALS; BRAIN ISCHEMIA; ENDOTHELIUM, VASCULAR; MALE; NEUROPROTECTIVE AGENTS; NEUTROPHIL INFILTRATION; PPAR ALPHA; PROCETOFEN; RATS; RATS, WISTAR; STROKE; SUPEROXIDES;

EID: 70449535878     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.08.002     Document Type: Article

References (37)

1. Bastide M., Bordet R., Pu Q., Robin E., Puisieux F., and Dupuis B. Relationship between inward rectifier potassium current impairment and brain injury after cerebral ischemia/reperfusion. J. Cereb. Blood Flow Metab. 19 (1999) 1309-1315
2. Bastide M., Gelé P., Pétrault O., Pu Q., Caliez A., Robin E., Deplanque D., Duriez P., and Bordet R. Delayed cerebrovascular protective effect of lipopolysaccharide in parallel to brain ischemic tolerance. J. Cereb. Blood Flow Metab. 23 (2003) 399-405
3. Bordet R., Ouk T., Petrault O., Gelé P., Gautier S., Laprais M., Deplanque D., Duriez P., Staels B., Fruchart J.C., and Bastide M. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem. Soc. Trans. 34 (2006) 1341-1346
4. Collino M., Aragno M., Mastrocola R., Benetti E., Gallicchio M., Dianzani C., Danni O., Thiemermann C., and Fantozzi R. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic. Biol. Med. 41 (2006) 579-589
5. Deplanque D., Gelé P., Pétrault O., Six I., Furman C., Bouly M., Nion S., Dupuis B., Leys D., Fruchart J.C., Cecchelli R., Staels B., Duriez P., and Bordet R. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J. Neurosci. 23 (2003) 6264-6271
6. del Zoppo G.J. Stroke and neurovascular protection. N. Engl. J. Med. 354 (2006) 553-555
7. Deguchi K., Hayashi T., Nagotani S., Sehara Y., Zhang H., Tsuchiya A., Ohta Y., Tomiyama K., Morimoto N., Miyazaki M., Huh N.H., Nakao A., Kamiya T., and Abe K. Reduction of cerebral infarction in rats by biliverdin associated with amelioration of oxidative stress. Brain Res. 10 1188 (2008) 1-8
8. Deplanque D., Masse I., Lefebvre C., Libersa C., Leys D., and Bordet R. Prior TIA, lipid-lowering drug use, and physical activity decrease ischemic stroke severity. Neurology 24 67(8) (2006) 1403-1410
9. Dirnagl U., Simon R.P., and Hallenbeck J.M. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 26 (2003) 248-254
10. Donnan G.A., Fisher M., Macleod M., and Davis S.M. Stroke. Lancet 371 (2008) 1612-1623
11. Endres M., and Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke 35 11 Suppl 1 (2004) 2708-2711
12. Endres M., Laufs U., Liao J.K., and Moskowitz M.A. Targeting eNOS for stroke protection. Trends Neurosci. 27 (2004) 283-289
13. Fagan S.C., Hess D.C., Hohnadel E.J., Pollock D.M., and Ergul A. Targets for vascular protection after acute ischemic stroke. Stroke 35 (2004) 2220-2225
14. Faraci F.M. Oxidative stress. The curse that underlies cerebral vascular dysfunction ?. Stroke 36 (2005) 186-188
15. Gautier S., Ouk T., Petrault O., Caron J., and Bordet R. Neutrophils contribute to intracerebral hemorrhages after recombinant tissue plasminogen activator treatment in cerebral ischemia. Br. J. Pharmacol. 156 (2009) 673-679
16. Gertz K., Laufs U., Lindauer U., Nickenig G., Böhm M., Dirnagl U., and Endres M. Withdrawal of statin treatment abrogates stroke protection in mice. Stroke 34 (2003) 551-557
17. Gidday J.M. Cerebral preconditioning and ischaemic tolerance. Nat. Rev. Neurosci. 7 (2006) 437-448
18. Goldstein L.B. Statins and ischemic stroke severity: cytoprotection. Curr. Atheroscler. Rep. 11 (2009) 296-300
19. Gursoy-Ozdemir Y., Can A., and Dalkara R. Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke 35 (2004) 1449-1453
20. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5 (2004) 347-360
21. Inoue H., Jiang X.F., Katayama T., Osada S., Umesono K., and Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci. Lett. 352 (2003) 203-206
22. Laufs U., Gertz K., Dirnagl U., Böhm M., Nickenig G., and Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 942 (2002) 23-30
23. Lo E.H. Experimental models, neurovascular mechanisms and translational issues in stroke research. Br J Pharmacol. 153 Suppl 1 (2008) S396-S405
24. Paxinos G., and Watson C. The Rat Brain Stereotaxic Coordinates (1986), Second ed. Academic Press Inc, London
25. Pétrault O., Bastide M., Cotelle N., Gelé P., Gautier S., Laprais M., Vamecq J., Duriez P., and Bordet R. The neuroprotective effect of the antioxidant flavonoid derivate di-tert-butylhydroxyphenyl is parallel to the preventive effect on post-ischemic Kir2.x impairment but not to post-ischemic endothelial dysfunction. Naunyn-Schmiedeberg's Arch. Pharmacol. 370 (2004) 395-403
26. Pétrault O., Ouk T., Gautier S., Laprais M., Gelé P., Bastide M., and Bordet R. Pharmacological neutropenia prevents endothelial dysfunction but not smooth muscle functions impairment induced by middle cerebral artery occlusion. Br. J. Pharmacol. 144 (2005) 1051-1058
27. Plaisier F., Bastide M., Ouk T., Pétrault O., Laprais M., Stolc S., and Bordet R. Stobadine-induced hastening of sensorimotor recovery after focal ischemia/reperfusion is associated with cerebrovascular protection. Brain Res. 1208 (2008) 240-249
28. Robinson K.M., Janes M.S., Pehar M., Monette J.S., Ross M.F., Hagen T.M., Murphy M.P., and Beckman J.S. Selective fluorescent imaging of superoxide in vivo using ethidium-based probes. Proc. Natl. Acad. Sci. U S A 10 103(41) (2006) 15038-15043
29. Romano J.G., and Sacco R.L. Progress in secondary stroke prevention. Ann. Neurol. 63 (2008) 418-427
30. Sironi L., Cimino M., Guerrini U., Cavio A.M., Lodetti B., Adsente M., Balduini W., Paoletti R., and Tremoli E. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 322-327
31. Stenzel-Poore M.P., Stevens S.L., King J.S., and Simon R.P. Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: a speculative synthesis. Stroke 38 2 Suppl (2007) 680-685
32. Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., and Landreth G.E. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130 (2005) 685-696
33. Takahashi M., and Macdonald R.L. Vascular aspects of neuroprotection. Neurol. Res. 26 (2004) 862-869
34. Touyz R.M., and Schiffrin E.L. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul. Pharmacol. 45 (2006) 19-28
35. Trivedi R.K., Kallem R.R., Mullangi R., and Srinivas N.R. Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study. J. Pharm. Biomed. Anal. 39 (2005) 661-669
36. Tureyen K., Kapadia R., Bowen K.K., Satriotomo I., Liang J., Feinstein D.L., and Vemuganti R. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. Neurochem. 101 (2007) 41-56
37. Yu A.Y., Keezer M.R., Zhu B., Wolfson C., and Côté R. Pre-stroke use of antihypertensives, antiplatelets, or statins and early ischemic stroke outcomes. Cerebrovasc. Dis. 27 (2009) 398-402